| Literature DB >> 35116103 |
Yang-Che Kuo1, Lo-Yip Yu2, Horng-Yuan Wang1, Ming-Jen Chen1, Ming-Shiang Wu3, Chun-Jen Liu4, Ying-Chun Lin5, Shou-Chuan Shih6, Kuang-Chun Hu7.
Abstract
Helicobacter pylori (H. pylori) has infected approximately fifty percent of humans for a long period of time. However, improvements in the public health environment have led to a decreased chance of H. pylori infection. However, a high infection rate is noted in populations with a high incidence rate of gastric cancer (GC). The worldwide fraction of GC attributable to H. pylori is greater than 85%, and a high H. pylori prevalence is noted in gastric mucosa-associated lymphoid tissue lymphoma patients. These results indicate that the majority of GC cases can be prevented if H. pylori infection is eliminated. Because H. pylori exhibits oral-oral or fecal-oral transmission, the relationship between this microorganism and other digestive tract malignant diseases has also attracted attention. This review article provides an overview of H. pylori and the condition of the whole gastrointestinal tract environment to further understand the correlation between the pathogen and the host, thus allowing improved realization of disease presentation. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.Entities:
Keywords: Gastrointestinal tract; Helicobacter pylori; Malignant disease
Year: 2022 PMID: 35116103 PMCID: PMC8790410 DOI: 10.4251/wjgo.v14.i1.55
Source DB: PubMed Journal: World J Gastrointest Oncol
Figure 1Estimated cumulative risk of incidence and mortality of gastroenterology tract malignancy disease in 2020, both sexes, ages 0-74 (reproduced from http://globocan.iarc.fr/).
Association with Helicobacter pylori infection and oral squamous cell carcinoma
|
|
|
|
| |
| Fernando | Betel Chewers (20/104; 19.2%) and non-betel chewers (4/69; 5.8%) | Serology | Case- control study | < 0.05 |
| Grandis | Case 57% | Serology | Case- control study | > 0.05 |
| Dayama | OR: 3.0; 95%CI: 0.34-26.4 | Serum and tissue samples (PCR and culture) | Case- control study | NA |
| Gupta | OR: 2.29; 95%CI: 0.61-8.68 | Serology, PCR, culture | Meta-analysis | NA |
| Meng | Case 35.3% | Serology, PCR, histochemical staining | Case- control study | 0.012 |
H. pylori: Helicobacter pylori; OR: Odds ratio; CI: Confidence interval; PCR: Polymerase chain reaction; NA: Not available.
Helicobacter pylori infection effect in whole gastroenterology tract malignant diseases
|
|
|
|
|
|
|
|
| Oral cavity | Squamous cell carcinoma | Non related | 1 min | |||
| Pharynx-larynx | Squamous cell carcinoma | Increased risk | 2.87 | 1.71-4.84 | < 0.05 | 1 s |
| Oesophagus | Squamous cell carcinoma | Non related | 4-8 s | |||
| Adenocarcinoma | Protected effect | 0.56 | 0.46-0.68 | < 0.05 | ||
| Stomach | Adenocarcinoma | Cause-effect | 5.9 | 3.4-10.3 | < 0.05 | 2-4 h |
| MALT lymphoma | Cause-effect | 1.96 | 1.0-3.9 | < 0.05 | ||
| Small intestine | Lymphoma | Non related | 6 h | |||
| Colorectum | Adenocarcinoma | Partial cause-effect | 1.7 | 1.64-1.76 | < 0.05 | 10 h to days |
| Lymphoma | Non related |
Influence of smoking and alcohol consumption on Helicobacter pylori and laryngeal carcinoma was not removed from their study. CI: Confidence interval; MALT: Mucosa-associated lymphoid tissue; H. pylori: Helicobacter pylori.
Association with Helicobacter pylori infection and pharyngeal-laryngeal cancer
|
|
|
|
|
|
| Zhou | Laryngeal CA: OR: 3.28; 95%CI: 1.91-5.63 | Histochemical, PCR, rapid urease test | Meta-analysis |
|
| Pharyngeal CA: OR: 1.35; 95%CI: 0.86-2.12 | = 0.188 | |||
| Siupsinskiene | Laryngeal CA: Case 46.2% and controls 9.1% | Rapid urease test | Case- control study |
|
| Zhou | Laryngeal CA: OR: 2.3 95%CI: 1.28-3.23 | Serology, histopathological methods | Meta-analysis |
|
| Pirzadeh | Laryngeal CA: Case 49.2% and controls 40% | Rapid urease test | Case- control study | NA |
OR: Odds ratio; CI: Confidence interval; PCR: Polymerase chain reaction; H. pylori: Helicobacter pylori; CA: Cancer; NA: Not available.
Association with Helicobacter pylori infection and Esophageal cancer
|
|
|
|
|
|
| Rokkas | EAC: 0.52 (95%CI: 0.37-0.73) | Serology and/or histology | Meta-analysis | EAC: |
| ESCC: 0.85 (95%CI: 0.55-1.33) | ESCC: | |||
| Islami | EAC: 0.56 (95%CI: 0.46-0.68) | Serology and/or histology | Meta-analysis | NA |
| ESCC: 1.10 (95%CI: 0.78-1.55) | ||||
| Nie | EAC: 0.57 (95%CI: 0.44-0.73) | Serology and/or histology; rapid urease test | Meta-analysis | NA |
| ESCC:1.16 (95%CI: 0.8.-1.60) | ||||
| Xie | EAC: 0.59 (95%CI: 0.51-0.68) | Serology and/or histology; rapid urease test | Meta-analysis | NA |
| ESCC: 0.97 (95%CI: 0.76-1.24) | ||||
| ESCC in Eastern: 0.66 (95%CI: 0.43-0.89) |
CI: Confidence interval; H. pylori: Helicobacter pylori; EAC: Esophageal adenocarcinoma; ESCC: Esophageal squamous-cell carcinoma; NA: Not available.
Association with Helicobacter pylori infection and gastric cancer
|
|
|
|
|
|
| Helicobacter and Cancer Collaborative Group[ | Non-cardia GC: OR: 5.9; 95%CI: 3.4-10.3 | Serology and/or histology | Meta-analysis |
|
| Huang | For cagA-positive OR: 1.64; 95%CI: 1.21-2.24 | Serology and/or histology | Meta-analysis | NA |
| Gastric cancer incidence decreased after | ||||
| Lee | Incidence rate ratio = 0.53; 95%CI: 0.44-0.64 | Serology and/or histology; rapid urease test | Meta-analysis | NA |
| Chiang | Reducing GC incidence of 0.53; 95%CI :0.3-0.69 | Rapid urease test | Prospective study |
|
In Helicobacter pylori-infected populations, cagA-positive strains further increased the risk for gastric cancer by 1.64-fold. GC: Gastric cancer; OR: Odds ratio; CI: Confidence interval; H. pylori: Helicobacter pylori; NA: Not available.
Association with Helicobacter pylori infection and gastrointestinal tract lymphoma
|
|
|
|
|
|
| Parsonnet | OR: 6.3; 95%CI: 2.0-19.9 | Serology | Case- control study | NA |
| Ishikura | OR: 2.14; 95%CI: 1.3-3.5 | Serology | Case- control study |
|
| Ishikura | OR: 1.96; 95%CI: 1.0-3.9 | Serology | Case- control study |
|
| Ishikura | OR: 1.92; 95%CI: 0.74-4.95 | Serology | Case- control study |
|
| Parsonnet | OR: 1.2; 95%CI: 0.5-3.0 | Serology | Case- control study | NA |
NHL: Non-Hodgkin’s lymphomas; MALT: Mucosa-associated lymphoid tissue; DLBCL: Diffuse large B-cell lymphoma; OR: Odds ratio; CI: Confidence interval; H. pylori: Helicobacter pylori; NA: Not available.
Association with Helicobacter pylori infection and colorectal adenoma/ cancer
|
|
|
|
|
|
| Hu | OR: 1.44; 95%CI: 1.2-1.73 | Rapid urease test | Retrospective |
|
| Sonnenberg | OR: 1.52; 95%CI: 1.46-1.57 | Histology | Retrospective | NA |
| Liou | Case 14.2% | 13C-UBT | Case-control study |
|
| Choi | OR: 1.49; 95%CI: 1.37-1.62 | Serology, histology, rapid urease test and 13C-UBT | Meta-analysis |
|
| Zuo | OR: 1.70; 95%CI: 1.64-1.76 | Serology, histology and rapid urease test | Meta-analysis | NA |
| Colorectal adenoma incidence decreased after | ||||
| Hu | HR: 3.04; 95%CI: 1.754-5.280 | Rapid urease test | Retrospective cohort |
|
For colorectal cancer.
Second rapid urease test (+) vs (-). 13C-UBT: 13C-urea breath test; OR: Odds ratio; CI: Confidence interval; H. pylori: Helicobacter pylori; HR: Hazard ratio; NA: Not available.